Abstract:BACKGROUND:Recent studies show that mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are the cause of the most common inherited and some sporadic forms of Parkinson's disease (PD). The molecular mechanism underlying the pathogenic role of LRRK2 mutations in PD remains unknown.METHODOLOGY/PRINCIPAL FINDINGS:Using affinity purification and mass spectrometric analysis, we investigated phosphorylation sites and binding proteins of LRRK2 purified from mouse brain. We identified multiple phosphorylation sites at N-terminus of LRRK2 including S910, S912, S935 and S973. Focusing on the high stoichiometry S935 phosphorylation site, we developed an anti-pS935 specific antibody and showed that LRRK2 is constitutively phosphorylated at S935 in various tissues (including brain) and at different ages in mice. We find that 14-3-3 proteins (especially isoforms γ and η) bind LRRK2 and this binding depends on phosphorylation of S935. The binding of 14-3-3, with little effect on dimer formation of LRRK2, confers protection of the phosphorylation status of S935. Furthermore, we show that protein kinase A (PKA), but not LRRK2 kinase itself, can cause the phosphorylation of LRRK2 at S935 in vitro and in cell culture, suggesting that PKA is a potential upstream kinase that regulates LRRK2 function. Finally, our study indicates that the common PD-related mutations of LRRK2, R1441G, Y1699C and G2019S, decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding of LRRK2.CONCLUSIONS/SIGNIFICANCE:LRRK2 is extensively phosphorylated in vivo, and the phosphorylation of specific sites (e.g. S935) determines 14-3-3 binding of LRRK2. We propose that 14-3-3 is an important regulator of LRRK2-mediated cellular functions. Our study suggests that PKA, a cAMP-dependent kinase involved in regulating dopamine physiology, is a potential upstream kinase that phosphorylates LRRK2 at S935. Furthermore, the reduction of phosphorylation/14-3-3 binding of LRRK2 due to the common familial PD-related mutations provides novel insight into the pathogenic mechanism of LRRK2-linked PD.

Screening of LRRK2 Interactants by Yeast 2-Hybrid Analysis.

Discovery of potent LRRK2 inhibitors by ensemble virtual screening strategy and bioactivity evaluation

Screening proteins interacting with human LKB1 by yeast two hybird system

Leucine-rich Repeat Kinase 2 (LRRK2) Interacts with Parkin, and Mutant LRRK2 Induces Neuronal Degeneration

Proximity proteomics reveals a co-evolved LRRK2-regulatory network linked to centrosomes

Advance of the Study on LRRK2 Gene in Parkinson's Disease

Tissue specific LRRK2 interactomes reveal a distinct striatal functional unit

LRRK2 binds to the Rab32 subfamily in a GTP-dependent manner via its armadillo domain

Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain.

Leucine-Rich Repeat Kinases

LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis

Expression Profiling and Localization Analysis of Parkinson's Disease Associated Protein LRRK2

Clinical characteristics and pathophysiological properties of newly discovered LRRK2 variants associated with Parkinson's disease

LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson’s disease patients

The LRRK2 kinase substrates RAB8a and RAB10 contribute complementary but distinct disease-relevant phenotypes in human neurons

Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers

Leucine-Rich Repeat Kinase 2 Binds to Neuronal Vesicles Through Protein Interactions Mediated by Its C-Terminal WD40 Domain

Leucine-rich Repeat Kinase 2 Interacts with Parkin, DJ-1 and PINK-1 in a Drosophila Melanogaster Model of Parkinson's Disease

Phosphorylation-dependent 14-3-3 Binding to LRRK2 is Impaired by Common Mutations of Familial Parkinson's Disease.

Expression Analysis Of Lrrk1, Lrrk2 And Lrrk2 Splice Variants In Mice

The Role of the LRRK2 Gene in Parkinsonism